Diagnóstico por componentes
El diagnóstico por componentes, basado en la identificación de sIgE contra las partículas de alérgenos específicos es, sin duda alguna, el futuro de la alergología. En 2022 se publicó una actualización de Molecular Allergology User Guide 2.0.8 Esta publicación presenta de manera pormenorizada el conocimiento más actual sobre la metodología de las determinaciones, la terminología y la importancia clínica de las distintas moléculas y sus familias: es una fuente de conocimiento actual en esta materia digna de recomendar. Barber y cols.9 presentaron los algoritmos diagnósticos prácticos que incluyen el diagnóstico molecular, la estimación del futuro riesgo y la selección de las eventuales técnicas terapéuticas, también la clasificación para la ITA.
Volver al artículo principal
Bibliografía
- Zuberbier T., Abdul Latiff A.H., Abuzakouk M. y cols., The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria, Allergy, 2022; 77: 734‑766
- Maurer M., Magerl M., Betschel S. y cols., The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update, Allergy, 2022; 77: 1961‑1990
- Wollenberg A., Kinberger M., Arents B. y cols., European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy, J. Eur. Acad. Dermatol. Venereol., 2022; 36: 1409‑1431
- Wollenberg A., Kinberger M., Arents B. y cols., European guideline (EuroGuiDerm) on atopic eczema – part II: non‑systemic treatments and treatment recommendations for special AE patient populations, J. Eur. Acad. Dermatol. Venereol., 2022; 36: 1904‑1926
- Sturm G.J., Herzog S.A., Aberer W. y cols., ß‑blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy, Allergy, 2021; 76: 2166‑2176
- Farraia M., Paciencia I., Castro Mendes F. y cols., Allergen immunotherapy for asthma prevention: a systematic review and meta‑analysis of randomized and non‑randomized controlled studies, Allergy, 2022; 77: 1719‑1735
- Ahlbeck L., Ahlberg E., Björkander J. y cols., Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen, Clin. Exp. Allergy, 2022; 52: 747‑75
- Hoffmann‑Sommergruber K., de las Vecillas L., Dramburg S. y cols., Molecular allergology user’s guide 2.0, EAACI, 2022; https://hub.eaaci.org/resources_guidelines/molecular-allergology-users-guide-2-0/ (acceso: 13.03.2023)
- Barber D., Diaz‑Perales A., Escribese M.M. y cols., Molecular allergology and its impact in specific allergy diagnosis and therapy, Allergy, 2021; 76: 3642‑3658
- Muraro A., Worm M., Alviani C. y cols., EAACI guidelines: Anaphylaxis (2021 update), Allergy, 2022; 77: 357‑377
- Blazowski L., Majak P., Kurzawa R. y cols., A severity grading system of food‑induced acute allergic reactions to avoid the delay of epinephrine administration, Ann. Allergy Asthma Immunol., 2021; 127: 462‑470.e2
- Ryan D., Flokstra‑de Blok B.M.J., Clark E. y cols., Allergic and hypersensitivity conditions in non‑specialist care: flow diagrams to support clinical practice, Allergy, 2022; 77: 2618‑2633
- Khan D.A, Banerji A., Blumenthal K.G. y cols., Drug allergy: a 2022 practice parameter update, J. Allergy Clin. Immunol. Pract., 2023; 11: 356‑368.e5.
- Pagani M., Bavbek S., Alvarez‑Cuesta E. y cols., Hypersensitivity reactions to chemotherapy: an EAACI Position Paper, Allergy, 2022; 77: 388‑403
- Bavbek S., Pagani M., Alvarez‑Cuesta E. y cols., Hypersensitivity reactions to biologicals: an EAACI position paper, Allergy, 2022; 77: 39‑54
- Muraro A., de Silva D., Halken S. y cols., Managing food allergy: GA2LEN guideline 2022, World Allergy Organ. J., 2022; doi: 10.1016/j.waojou.2022.100 687
- Brozek J.L., Firmino R.T., Bognanni A. y cols., World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) Guideline update – XIV –Recommendations on CMA immu-notherapy, World Allergy Organ. J., 2022; doi: 10.1016/j.waojou.2022.100 646
- Rank M.A., Chu D.K., Bognanni A. y cols., The joint task force on practice parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis, J. Allergy Clin. Immunol., 2023; 151: 386‑398
- Gevaert P., Omachi T.A., Corren J. y cols., Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials, J. Allergy Clin. Immunol., 2020; 146: 595‑605
- Han J.K., Bachert C., Fokkens W. y cols., Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double‑blind, placebo‑controlled, phase 3 trial, Lancet Respir. Med., 2021; 9: 1141‑1153
- Bachert C., Han J.K., Desrosiers M. y cols., Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‑24 and LIBERTY NP SINUS‑52): results from two multicentre, randomised, double‑blind, placebo‑controlled, parallel‑group phase 3 trials, Lancet, 2019; 394: 1638‑1650
- Dellon E.S., Rothenberg M.E., Collins M.H. y cols., Dupilumab in adults and adolescents with eosinophilic esophagitis, N. Engl. J. Med., 2022; 387: 2317‑2330
- Agache I., Antolin‑Amerigo D., de Blay F. y cols., EAACI position paper on the clinical use of the bronchial allergen challenge: unmet needs and research priorities, Allergy, 2022; 77: 1667‑1684
- Skypala I.J., Jeimy S., Brucker H. y cols., Cannabis‑related allergies: an international overview and consensus recommendations, Allergy, 2022; 77: 2038‑2052